Why Covid Antibody Drugs Go Unused as Need Soars

While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.

Covid Antibody Drugs Go Unused as Need Soars

While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.

Why Covid Antibody Drugs Go Unused as Need Soars

While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.

Covid Meds Are Scarce, but Not for Trump Cronies

Rudy Giuliani got monoclonal antibodies. You probably can’t.

Covid Meds Are Scarce, but Not for Trump Cronies

Rudy Giuliani got monoclonal antibodies. You probably can’t.

Trump and Friends Got Coronavirus Care Many Others Couldn’t

Rudolph W. Giuliani became the latest in President Trump’s inner circle to boast about the treatment he received for Covid-19, as hospitals across the country ration care.

Model-based Strategy to Guide the Choice of Clinical Doses for ADC

Chemotherapy has been a powerful method for fighting cancer for decades. One of the most effective therapies available, it is also known for weakening the patient and causing harsh side effects like pain, nausea, and hair loss. This is because in its zeal to attack cancer cells, chemo also kills healthy cells.

Enter antibody-drug
conjugates (ADCs). This promising anti-cancer therapy is designed to
specifically target tumor cells, leaving the body’s healthy cells unharmed.
Developing safe and effective ADCs is not without its difficulties, though, and
more of those challenges need to be overcome before ADCs can replace the role
of chemotherapy.  

Pharmacokinetic-pharmacodynamic
(PKPD) scientists at the French pharmaceutical multinational Pierre Fabre are
doing their part. They have developed novel modelling and simulation-based
tools to guide the choice of the most promising safe and efficacious dosing
regimen of an innovative antibody drug conjugate.

On October 27, Dr.
Julie Desrivot Quénelle, PKPD Project Lead at Pierre Fabre, will give a
presentation on her team’s work in a free webinar titled “Model-based strategy
to guide the choice of clinical doses for ADC,” hosted by Olivier Barberan,
Director of Translational Medicine Solutions at Elsevier. It’s a great
opportunity to learn more about this important area of cancer research.

To join the webinar, register here.

Qiagen to Launch Digital Test for Detecting SARS-CoV-2 Antibodies in the US

Shots:

  • Qiagen reports the launch of the Access Anti-SARS-CoV-2 Total test that runs on a portable device and provides accurate results on Total Ig Abs (IgA, IgM, IgG) in 10mins. The device can process up to 8 samples simultaneously or up to 32 tests/hour
  • The test was developed in collaboration with Ellume, following the US FDA’s EUA submission. The companies plan to launch it in the US in Aug’2020 while anticipates the CE-IVD marking in the EU with the initiation of commercialization in other markets in coming weeks
  • The test is performed on eHub & eStick system provides rapid qualitative serological in-vitro detection of total antibodies to SARS-CoV-2 in plasma & serum and has demonstrated 100% sensitivity & specificity

Click here ­to­ read full press release/ article | Ref: Qiagen | Image: Fierce Biotech

Related News: Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains